This content was originally shared by a registered user, but access has expired. Create a free account to gain permanent access to all PracticeUpdate content.
Already Have An Account? Log in Now
Abiraterone Acetate Plus Prednisone in Newly Diagnosed High-Risk Metastatic Castration-Sensitive Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Abiraterone Acetate Plus Prednisone in Patients With Newly Diagnosed High-Risk Metastatic Castration-Sensitive Prostate Cancer (LATITUDE): Final Overall Survival Analysis of a Randomised, Double-Blind, Phase 3 Trial
Lancet Oncol 2019 Apr 12;[EPub Ahead of Print], K Fizazi, N Tran, L Fein, N Matsubara, A Rodriguez-Antolin, BY Alekseev, M Özgüroğlu, D Ye, S Feyerabend, A Protheroe, G Sulur, Y Luna, S Li, S Mundle, KN ChiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.